Favet joins the Netanya, Israel–based heart failure congestion management company with more than 20 years of executive-level experience. He most recently was CEO of Neuropace, where he led a commercial expansion and took the company public in 2021.
“Mike brings a distinguished track record of successful leadership in medtech and is ideally suited to build Revamp Medical from the solid foundation being demonstrated in the U.S. Early Feasibility Study through the pivotal trial to support FDA approval,” Revamp Medical Board Director Mike Berman said in a news release. “With over 20 years of senior executive experience leading innovation and developing new therapies in medical technologies, Mike brings invaluable experience, skills and insight that will deliver this important medical advancement to patients. At the same time, on behalf of the Revamp Medical board, I would like to acknowledge and thank Yael Shohat for all that she has done to lead the Company for the past 18 months.”
Favet replaces Yael Shohat, who will remain on the executive team as chief operations officer.
Prior to leading Neuropace, Favet was managing director for KCK Medtech and has held senior management positions at various medtech companies, including Advanced Cardiac Therapeutics, Sonitus Medical, Boston Scientific and Guidant.
“I am thrilled for the opportunity to join Revamp Medical at this significant juncture,” Favet said. “Early clinical study results with the Doraya device, including the interim results of the U.S. early feasibility study presented by Dr. Zier at the recent THT conference, show great promise to help patients admitted to the hospital with acute decompensated heart failure. I look forward to further building the clinical evidence and bringing Doraya to the market. I am excited to work with our talented team to build on the company’s success.”